214610 — MiCo BioMed Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for MiCo BioMed Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	45,672	30,302	16,111	5,367	4,640
Cost of Revenue
Gross Profit	20,919	14,787	-403	-6,861	-6,018
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	42,244	41,197	43,090	25,725	25,292
Operating Profit	3,428	-10,895	-26,978	-20,357	-20,652
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-5,789	-10,598	-38,932	-25,808	-29,335
Provision for Income Taxes
Net Income After Taxes	-5,776	-10,585	-38,919	-25,795	-28,100
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-5,776	-10,575	-38,893	-25,774	-29,931
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-5,776	-10,575	-38,893	-25,774	-29,931
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-253	-372	-1,335	-1,070	-627
Dividends per Share